secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001380106-24-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems Q4 revenue $6.3M (+45% YoY); guides FY2024 revenue ≥$27M
-------------------------------------------------------------------------------

- Q4 2023 revenue $6.3M (+45% YoY); placed 6 Growth Direct systems, highest since Q3 2021.
- FY2023 revenue $22.5M (+31% YoY); net loss $52.5M vs $60.8M in 2022, loss narrowed.
- Gross margin improved to near breakeven (-3%) from -59% in Q4 2022 on cost actions.
- Cash $95M, no debt; expected runway into H2 2026.
- FY2024 guidance: revenue ≥$27M, at least 20 system placements; new Rapid Sterility app by mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010624000058/0001380106-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010624000058/rpid-20240301.htm
  HTML page:      https://secwatch.observer/filing/0001380106-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer